

# Ahmet Dogan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/754329/publications.pdf>

Version: 2024-02-01

244  
papers

11,531  
citations

34105

52  
h-index

33894

99  
g-index

247  
all docs

247  
docs citations

247  
times ranked

13828  
citing authors

#	ARTICLE	IF	CITATIONS
1	Best Practices in CD30 Immunohistochemistry Testing, Interpretation, and Reporting: An Expert Panel Consensus. Archives of Pathology and Laboratory Medicine, 2023, 147, 79-86.	2.5	1
2	Reduced Plasmacytoid Dendritic Cell Output Is Associated With High Risk in Low-grade Myelodysplastic Syndrome. HemaSphere, 2022, 6, e685.	2.7	4
3	Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma. Blood Cancer Journal, 2022, 12, 29.	6.2	1
4	T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 285-308.	4.9	58
5	CD19 epitope masking by tafasitamab leads to delays in subsequent use of CD19 CAR T-cell therapy in two patients with aggressive mature B-cell lymphomas. Leukemia and Lymphoma, 2022, 63, 751-754.	1.3	10
6	<sc>PD</sc> improves accurate detection of Sezary cells by flow cytometry in peripheral blood in mycosis fungoides/Sezary syndrome. Cytometry Part B - Clinical Cytometry, 2022, 102, 189-198.	1.5	5
7	The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood, 2022, 140, 1229-1253.	1.4	512
8	First report of bilateral breast-implant associated anaplastic large cell lymphoma caused by identical T-cell clone. Leukemia and Lymphoma, 2022, 63, 2747-2750.	1.3	2
9	Next-generation ALK inhibitors are highly active in ALK-positive large B-cell lymphoma. Blood, 2022, 140, 1822-1826.	1.4	8
10	14-Color single tube for flow cytometric characterization of CD5+ B-LPDs and high sensitivity automated minimal residual disease quantitation of CLL/SLL. Cytometry Part B - Clinical Cytometry, 2021, 100, 509-518.	1.5	11
11	Myeloid/lymphoid neoplasms with eosinophilia/ basophilia and ETV6-ABL1 fusion: cell-of-origin and response to tyrosine kinase inhibition. Haematologica, 2021, 106, 614-618.	3.5	8
12	Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era. Blood, 2021, 137, 39-48.	1.4	38
13	Plasmacytoid dendritic cell expansion defines a distinct subset of <i>RUNX1</i>-mutated acute myeloid leukemia. Blood, 2021, 137, 1377-1391.	1.4	51
14	Initial Whole-Genome Sequencing of Plasma Cell Neoplasms in First Responders and Recovery Workers Exposed to the World Trade Center Attack of September 11, 2001. Clinical Cancer Research, 2021, 27, 2111-2118.	7.0	5
15	Next generation sequencing of breast implant-associated anaplastic large cell lymphomas reveals a novel <i>STAT3&JAK2</i> fusion among other activating genetic alterations within the <i>JAK&STAT</i> pathway. Breast Journal, 2021, 27, 314-321.	1.0	29
16	Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing. Journal of Molecular Diagnostics, 2021, 23, 181-199.	2.8	19
17	Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities. Nature Communications, 2021, 12, 1861.	12.8	68
18	Involved-site radiotherapy for <i>Helicobacter pylori</i>-independent gastric MALT lymphoma: 26 years of experience with 178 patients. Blood Advances, 2021, 5, 1830-1836.	5.2	17

#	ARTICLE	IF	CITATIONS
19	OncoTree: A Cancer Classification System for Precision Oncology. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 221-230.	2.1	51
20	Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial. <i>Lancet Haematology</i> , 2021, 8, e422-e432.	4.6	50
21	Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma. <i>JAMA Oncology</i> , 2021, 7, 862.	7.1	63
22	Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse. <i>Blood Cancer Journal</i> , 2021, 11, 113.	6.2	35
23	Hairy Cell Leukemia Masquerading as CD5+ Lymphoproliferative Disease: The Importance of BRAF V600E Testing in Diagnosis and Treatment. <i>JCO Precision Oncology</i> , 2021, 5, 1035-1039.	3.0	3
24	EZH2 expression is associated with inferior overall survival in mantle cell lymphoma. <i>Modern Pathology</i> , 2021, 34, 2183-2191.	5.5	7
25	Copy number signatures predict chromothripsis and clinical outcomes in newly diagnosed multiple myeloma. <i>Nature Communications</i> , 2021, 12, 5172.	12.8	27
26	Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 3109-3117.	1.6	97
27	TP53 Combined Phenotype Score Is Associated with the Clinical Outcome of TP53-Mutated Myelodysplastic Syndromes. <i>Cancers</i> , 2021, 13, 5502.	3.7	2
28	A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas. <i>Blood</i> , 2021, 138, 2828-2837.	1.4	65
29	The Genomic Landscape of Waldenström Macroglobulinemia Reveals Sustained Germinal Center Activity and Late-Developing Copy Number Aberrations. <i>Blood</i> , 2021, 138, 2394-2394.	1.4	0
30	TP53 Mutations Identify High-Risk Peripheral T-Cell Lymphoma Patients Treated with CHOP-Based Chemotherapy. <i>Blood</i> , 2021, 138, 1367-1367.	1.4	2
31	Quantitative Off-Target Detection of Epstein-Barr Virus-Derived DNA in Routine Molecular Profiling of Hematopoietic Neoplasms by Panel-Based Hybrid-Capture Next-Generation Sequencing. <i>Journal of Molecular Diagnostics</i> , 2021, , .	2.8	2
32	Abnormal B-Cell Lymphoblasts in myelodysplastic syndromes and myeloproliferative neoplasms other than chronic myeloid leukemia. <i>Cytometry Part B - Clinical Cytometry</i> , 2021, , .	1.5	2
33	Erdheim-Chester disease with concomitant Rosai-Dorfman like lesions: a distinct entity mainly driven by <i>MAP2K1</i> . <i>Haematologica</i> , 2020, 105, e5-e8.	3.5	34
34	Pilot Study of Bortezomib and Dexamethasone Pre- and Post-Risk-Adapted Autologous Stem Cell Transplantation in AL Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 204-208.	2.0	10
35	Clonally-Related CD5+ CLL/SLL and CD10+ high grade B-cell lymphoma suggests common neoplastic progenitor with branched disease evolution, with therapeutic implications. <i>Leukemia and Lymphoma</i> , 2020, 61, 460-464.	1.3	0
36	Incidence of benign and malignant peri-implant fluid collections and masses on magnetic resonance imaging in women with silicone implants. <i>Cancer Medicine</i> , 2020, 9, 3261-3267.	2.8	13

#	ARTICLE	IF	CITATIONS
37	Experimental and numerical investigation of drainage mechanisms at sports fields under simulated rainfall. <i>Journal of Hydrology</i> , 2020, 580, 124251.	5.4	19
38	Clinical characteristics and prognosis of cardiac amyloidosis defined by mass spectrometry-based proteomics in an Australian cohort. <i>Internal Medicine Journal</i> , 2020, , .	0.8	1
39	Accelerated single cell seeding in relapsed multiple myeloma. <i>Nature Communications</i> , 2020, 11, 3617.	12.8	41
40	Targeted genomic analysis of cutaneous T cell lymphomas identifies a subset with aggressive clinicopathological features. <i>Blood Cancer Journal</i> , 2020, 10, 116.	6.2	6
41	Chemical composition and biological activities of endemic <i>Tripleurospermum conoclinium</i> (Boiss. & Balansa) Hayek essential oils. <i>Flavour and Fragrance Journal</i> , 2020, 35, 713-721.	2.6	8
42	Extra copies of MYC, BCL2, and BCL6 and outcome in patients with diffuse large B-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 3382-3390.	5.2	10
43	<i>FGFR1</i> Rearrangement Guides Diagnosis and Treatment of a Trilineage B, T, and Myeloid Mixed Phenotype Acute Leukemia. <i>JCO Precision Oncology</i> , 2020, 4, 937-943.	3.0	2
44	Revealing the Impact of Structural Variants in Multiple Myeloma. <i>Blood Cancer Discovery</i> , 2020, 1, 258-273.	5.0	81
45	Breast Implant-associated Anaplastic Large Cell Lymphoma Incidence. <i>Annals of Surgery</i> , 2020, 272, 403-409.	4.2	47
46	Hairy cell leukemia expresses programmed death-1. <i>Blood Cancer Journal</i> , 2020, 10, 115.	6.2	4
47	Aggressive Hematopoietic Malignancy Characterized by Biallelic Loss of SMARCB1. <i>JCO Precision Oncology</i> , 2020, 4, 1280-1284.	3.0	1
48	Impact of allogeneic hematopoietic cell transplantation on immune evasive mechanisms in relapsed refractory large B-cell lymphoma. <i>Bone Marrow Transplantation</i> , 2020, 55, 2331-2334.	2.4	0
49	Mass Spectrometry-Based Method Targeting Ig Variable Regions for Assessment of Minimal Residual Disease in Multiple Myeloma. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 901-911.	2.8	22
50	A Novel JAK1 Mutant Breast Implant-Associated Anaplastic Large Cell Lymphoma Patient-Derived Xenograft Fostering Pre-Clinical Discoveries. <i>Cancers</i> , 2020, 12, 1603.	3.7	11
51	Bright PD-1 expression by flow cytometry is a powerful tool for diagnosis and monitoring of angioimmunoblastic T-cell lymphoma. <i>Blood Cancer Journal</i> , 2020, 10, 32.	6.2	9
52	B-cell maturation antigen expression across hematologic cancers: a systematic literature review. <i>Blood Cancer Journal</i> , 2020, 10, 73.	6.2	36
53	The serine hydroxymethyltransferase-2 (SHMT2) initiates lymphoma development through epigenetic tumor suppressor silencing. <i>Nature Cancer</i> , 2020, 1, 653-664.	13.2	35
54	Genetic basis for iMCD-TAFRO. <i>Oncogene</i> , 2020, 39, 3218-3225.	5.9	14

#	ARTICLE	IF	CITATIONS
55	Risk of breast implant associated anaplastic large cell lymphoma (BIA-ALCL) in a cohort of 3546 women prospectively followed long term after reconstruction with textured breast implants. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2020, 73, 841-846.	1.0	128
56	Histiocytic sarcoma arising in patient with history of clonally related germ cell tumour and myelodysplastic syndrome. <i>British Journal of Haematology</i> , 2020, 188, 482-482.	2.5	5
57	Neurologic and oncologic features of Erdheim-Chester disease: a 30-patient series. <i>Neuro-Oncology</i> , 2020, 22, 979-992.	1.2	31
58	Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma. <i>Cancer Discovery</i> , 2020, 10, 440-459.	9.4	103
59	Baseline FDG-PET/CT detects bone marrow involvement in follicular lymphoma and provides relevant prognostic information. <i>Blood Advances</i> , 2020, 4, 1812-1823.	5.2	22
60	Germ cell tumors and associated hematologic malignancies evolve from a common shared precursor. <i>Journal of Clinical Investigation</i> , 2020, 130, 6668-6676.	8.2	28
61	Whole-Genome Sequencing Reveals Evidence of Two Biologically and Clinically Distinct Entities: Progressive <i>versus</i> Stable Myeloma Precursor Disease. <i>Blood</i> , 2020, 136, 47-48.	1.4	2
62	CD5-Positive Marginal Zone Lymphoma: Clinical Characteristics of the MSKCC Cohort, and Comparison with the CD5-Negative Population. <i>Blood</i> , 2020, 136, 50-51.	1.4	2
63	Clonal hematopoiesis in angioimmunoblastic T-cell lymphoma with divergent evolution to myeloid neoplasms. <i>Blood Advances</i> , 2020, 4, 2261-2271.	5.2	61
64	T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 4640-4647.	5.2	50
65	[18F]FDG-PET/CT Radiomics for Prediction of Bone Marrow Involvement in Mantle Cell Lymphoma: A Retrospective Study in 97 Patients. <i>Cancers</i> , 2020, 12, 1138.	3.7	24
66	Molecular Genetic Analysis With Flow Cytometry Sorting Identifies Angioimmunoblastic T-Cell Lymphoma and Concomitant <i>de novo</i> Myelodysplastic Syndrome Arising From the Same Hematopoietic Progenitor. <i>Journal of Hematology (Brossard, Quebec)</i> , 2020, 9, 140-146.	1.0	6
67	Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Patients with Multiple Myeloma Treated with Continuous Lenalidomide Maintenance Therapy: A Clinical and Correlative Phase 2 Study. <i>Blood</i> , 2020, 136, 18-19.	1.4	0
68	Frontline Sequential Immunochemotherapy Plus Lenalidomide for Mantle Cell Lymphoma Incorporating MRD Evaluation: Phase II, Investigator-Initiated, Single-Center Study. <i>Blood</i> , 2020, 136, 11-12.	1.4	6
69	Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy in Newly Diagnosed Multiple Myeloma: Final Results from a Clinical and Correlative Phase 2 Study. <i>Blood</i> , 2020, 136, 7-7.	1.4	1
70	The Genomic Complexity of Multiple Myeloma Precursor Disease Can be Predicted Using Copy Number Signatures on Targeted Sequencing and SNP Array Data. <i>Blood</i> , 2020, 136, 10-10.	1.4	1
71	Initial Whole Genome Sequencing of Plasma Cell Neoplasms in First Responders and Recovery Workers Exposed to the World Trade Center Attack of September 11, 2001. <i>Blood</i> , 2020, 136, 50-51.	1.4	0
72	Clinical Characteristics and Follow-up Post-Surgery of Women with Bia-ALCL Operated at a Single Institution. <i>Blood</i> , 2020, 136, 32-33.	1.4	0

#	ARTICLE	IF	CITATIONS
73	Copy Number Signatures Predict Chromothripsis and Poor Clinical Outcome in Newly Diagnosed Multiple Myeloma Patients. <i>Blood</i> , 2020, 136, 52-53.	1.4	2
74	Biologically active compounds from two members of the Asteraceae family: <i>Tragopogon dubius</i> Scop. and <i>Tussilago farfara</i> L.. <i>Journal of Biomolecular Structure and Dynamics</i> , 2019, 37, 3269-3281.	3.5	20
75	Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma. <i>JAMA Oncology</i> , 2019, 5, 1293.	7.1	57
76	Altered Nuclear Export Signal Recognition as a Driver of Oncogenesis. <i>Cancer Discovery</i> , 2019, 9, 1452-1467.	9.4	60
77	CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma. <i>Blood</i> , 2019, 134, 626-635.	1.4	59
78	Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark. <i>Blood</i> , 2019, 134, 678-687.	1.4	65
79	Fibrinogen alpha amyloidosis: insights from proteomics. <i>Expert Review of Proteomics</i> , 2019, 16, 783-793.	3.0	24
80	Serial treatment of relapsed/refractory multiple myeloma with different BCMA-targeting therapies. <i>Blood Advances</i> , 2019, 3, 2487-2490.	5.2	35
81	Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse. <i>Blood Cancer Journal</i> , 2019, 9, 50.	6.2	75
82	Efficacy of MEK inhibition in patients with histiocytic neoplasms. <i>Nature</i> , 2019, 567, 521-524.	27.8	222
83	Clinical presentation determines selection of patients for initial observation in mantle cell lymphoma. <i>Haematologica</i> , 2019, 104, e163-e166.	3.5	17
84	Recurrent somatic JAK3 mutations in NK-cell enteropathy. <i>Blood</i> , 2019, 134, 986-991.	1.4	42
85	Prognostic and Predictive Biomarkers in Diffuse Large B-cell Lymphoma. <i>Surgical Pathology Clinics</i> , 2019, 12, 699-707.	1.7	13
86	Divergent clonal evolution of a common precursor to mantle cell lymphoma and classic Hodgkin lymphoma. <i>Journal of Physical Education and Sports Management</i> , 2019, 5, a004259.	1.2	8
87	Pioneers of Breast Implant-Associated Anaplastic Large Cell Lymphoma: History from Case Report to Global Recognition. <i>Plastic and Reconstructive Surgery</i> , 2019, 143, 7S-14S.	1.4	31
88	Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma. <i>Blood Cancer Journal</i> , 2019, 9, 101.	6.2	40
89	Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 330-342.	2.8	69
90	<i>Paeonia arietina</i> and <i>Paeonia kesrounansis</i> bioactive constituents: NMR, LC-DAD-MS fingerprinting and in vitro assays. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 165, 1-11.	2.8	24

#	ARTICLE	IF	CITATIONS
91	Breast implant-associated anaplastic large cell lymphoma: Clinical and imaging findings at a large US cancer center. <i>Breast Journal</i> , 2019, 25, 69-74.	1.0	21
92	Immunohistochemical Detection of $\beta$ T Lymphocytes in Formalin-fixed Paraffin-embedded Tissues. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2019, 27, 581-583.	1.2	31
93	Noncovalent inhibitors reveal BTK gatekeeper and auto-inhibitory residues that control its transforming activity. <i>JCI Insight</i> , 2019, 4, .	5.0	17
94	Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell Lymphoma. <i>Blood</i> , 2019, 134, 4019-4019.	1.4	20
95	Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Phase 2 Study. <i>Blood</i> , 2019, 134, 3127-3127.	1.4	2
96	Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple Myeloma: A Clinical and Correlative Phase 2 Study. <i>Blood</i> , 2019, 134, 862-862.	1.4	34
97	First Description of B Cell Maturation Antigen Expression in Light Chain Amyloidosis. <i>Blood</i> , 2019, 134, 5452-5452.	1.4	5
98	Genomic Profiling of Mantle Cell Lymphoma Suggests Poor-Risk Profile Is Present at Diagnosis and Does Not Arise By Tumor Evolution. <i>Blood</i> , 2019, 134, 22-22.	1.4	7
99	Central Nervous System Prophylaxis with High-Dose Intravenous Methotrexate or Intrathecal Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma and High-Risk of CNS Relapse Treated in the Rituximab Era. <i>Blood</i> , 2019, 134, 1619-1619.	1.4	9
100	Contemporary Outcomes in HTLV-1-Associated Adult T-Cell Leukemia/Lymphoma: Single-Institution Experience. <i>Blood</i> , 2019, 134, 2850-2850.	1.4	1
101	Incidence of Delayed Seromas and Related Risk of Bia-ALCL in a Cohort of 3521 Breast Cancer Women with Textured Implants Prospectively Followed Long Term. <i>Blood</i> , 2019, 134, 2842-2842.	1.4	0
102	Aberrant SYK Expression As a Potential Therapeutic Target in T/NK Cell Neoplasms. <i>Blood</i> , 2019, 134, 3978-3978.	1.4	1
103	CD4 Lymphocytes and T Regulatory Cells Show Distinct Phenotypes in Follicular Lymphoma and Classical Hodgkin Lymphoma Which May Account for Differences in Responses to Checkpoint Therapy. <i>Blood</i> , 2019, 134, 1513-1513.	1.4	0
104	Annotation of Somatic Genomic Variants in Hematologic Diseases Using OncoKB, a Precision Oncology Knowledgebase. <i>Blood</i> , 2019, 134, 2148-2148.	1.4	3
105	Transformation of monoclonal B lymphocytosis to Epstein-Barr virus-positive large B-cell lymphoma with intermediate features between diffuse large B-cell lymphoma and classic Hodgkin lymphoma. <i>AJSP Review and Reports</i> , 2019, 24, 207-211.	0.1	0
106	Single-agent dabrafenib for <i>BRAF</i> <sup>V600E</sup> -mutated histiocytosis. <i>Haematologica</i> , 2018, 103, e177-e180.	3.5	40
107	Tumor suppressor CD99 is downregulated in plasma cell neoplasms lacking CCND1 translocation and distinguishes neoplastic from normal plasma cells and B-cell lymphomas with plasmacytic differentiation from primary plasma cell neoplasms. <i>Modern Pathology</i> , 2018, 31, 881-889.	5.5	8
108	Rainfall simulator for investigating sports field drainage processes. <i>Measurement: Journal of the International Measurement Confederation</i> , 2018, 125, 360-370.	5.0	8



#	ARTICLE	IF	CITATIONS
109	Multiple Myeloma and Its Precursor Disease Among Firefighters Exposed to the World Trade Center Disaster. <i>JAMA Oncology</i> , 2018, 4, 821.	7.1	38
110	A susceptibility locus for classical Hodgkin lymphoma at 8q24 near <i>MYC</i> predicts patient outcome in two independent cohorts. <i>British Journal of Haematology</i> , 2018, 180, 286-290.	2.5	13
111	The histopathology of Erdheim-Chester disease: a comprehensive review of a molecularly characterized cohort. <i>Modern Pathology</i> , 2018, 31, 581-597.	5.5	102
112	Phenolic components and assessment of biological properties of <i>Tchihatchewia isatidea</i> Boiss. extracts: Docking and functional approaches for designing novel products. <i>Food and Chemical Toxicology</i> , 2018, 111, 423-431.	3.6	7
113	Novel iatrogenic amyloidosis caused by peptide drug liraglutide: a clinical mimic of AL amyloidosis. <i>Haematologica</i> , 2018, 103, e610-e612.	3.5	11
114	HPLC-MS/MS-based metabolic profiling and pharmacological properties of extracts and infusion obtained from <i>Amelanchier parviflora</i> var. <i>dentata</i> . <i>Industrial Crops and Products</i> , 2018, 124, 699-706.	5.2	12
115	Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models. <i>Nature Communications</i> , 2018, 9, 2024.	12.8	80
116	Peripheral T-cell lymphoma – are we making progress?. <i>Best Practice and Research in Clinical Haematology</i> , 2018, 31, 306-314.	1.7	8
117	New insights into the in vitro biological effects, in silico docking and chemical profile of clary sage – <i>Salvia sclarea</i> L. <i>Computational Biology and Chemistry</i> , 2018, 75, 111-119.	2.3	40
118	Chemical Composition, Anti-Inflammatory, Antioxidant and Antimicrobial Activity of Essential Oil from Aerial Parts of <i>Chaerophyllum aromaticum</i> L. from Turkey. <i>Journal of Essential Oil-bearing Plants: JEOP</i> , 2018, 21, 563-569.	1.9	5
119	T-cell receptor expression and T <sub>H</sub> 1+ T-cell infiltrates in primary cutaneous T-cell lymphoma and other cutaneous T-cell lymphoproliferative disorders. <i>Histopathology</i> , 2018, 73, 653-662.	2.9	24
120	Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay. <i>Blood Cancer Journal</i> , 2018, 8, 60.	6.2	25
121	The Combination of Duvelisib, a PI3K-Î³ Inhibitor, and Romidepsin Is Highly Active in Relapsed/Refractory Peripheral T-Cell Lymphoma with Low Rates of Transaminitis: Results of Parallel Multicenter, Phase 1 Combination Studies with Expansion Cohorts. <i>Blood</i> , 2018, 132, 683-683.	1.4	28
122	Clinical Responses and Pharmacokinetics of MCARH171, a Human-Derived Bcma Targeted CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma: Final Results of a Phase I Clinical Trial. <i>Blood</i> , 2018, 132, 959-959.	1.4	71
123	Initial Results of a Phase II Study of Sequential Chemotherapy and Lenalidomide Followed By Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma. <i>Blood</i> , 2018, 132, 2880-2880.	1.4	1
124	Romidepsin activity in T follicular helper(TFH)-phenotype PTCL versus non TFH treated on the same clinical trials.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7509-7509.	1.6	5
125	Circulating Lymphoma Cells in Mycosis Fungoides/Sezary Syndrome Show Heterogeneity of the Cell-of-Origin and Variable PD-1 Expression By Flow Cytometric Analysis. <i>Blood</i> , 2018, 132, 1624-1624.	1.4	1
126	<i>FCGR3A</i> polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts. <i>Hematological Oncology</i> , 2017, 35, 447-455.	1.7	9



#	ARTICLE	IF	CITATIONS
127	International, evidence-based consensus diagnostic criteria for HHV-8“negative/idiopathic multicentric Castleman disease. <i>Blood</i> , 2017, 129, 1646-1657.	1.4	381
128	Immunophenotypic evidence for reactive polyclonal marrow plasmacytosis in multiple myeloma patients receiving lenalidomide maintenance. <i>Leukemia and Lymphoma</i> , 2017, 58, 2962-2965.	1.3	4
129	Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. <i>Cancer Discovery</i> , 2017, 7, 1018-1029.	9.4	302
130	Identification and Targeting of Kinase Alterations in Histiocytic Neoplasms. <i>Hematology/Oncology Clinics of North America</i> , 2017, 31, 705-719.	2.2	20
131	Bioactivities of <i>Achillea phrygia</i> and <i>Bupleurum croceum</i> based on the composition of phenolic compounds: In Vitro and in silico approaches. <i>Food and Chemical Toxicology</i> , 2017, 107, 597-608.	3.6	20
132	Clarifying immunoglobulin gene usage in systemic and localized immunoglobulin light-chain amyloidosis by mass spectrometry. <i>Blood</i> , 2017, 129, 299-306.	1.4	99
133	Amyloidosis: Insights from Proteomics. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2017, 12, 277-304.	22.4	72
134	An ethnobotanical study of medicinal plants in Acipayam (Denizli-Turkey). <i>Journal of Herbal Medicine</i> , 2017, 10, 64-81.	2.0	72
135	Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma. <i>Lupus Science and Medicine</i> , 2017, 4, e000187.	2.7	15
136	MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods. <i>Blood Advances</i> , 2017, 1, 728-732.	5.2	84
137	Development and Evaluation of a Human Single Chain Variable Fragment (scFv) Derived Bcma Targeted CAR T Cell Vector Leads to a High Objective Response Rate in Patients with Advanced MM. <i>Blood</i> , 2017, 130, 742-742.	1.4	92
138	In Vitro, In Vivo, and Parallel Phase I Evidence Support the Safety and Activity of Duvelisib, a PI3K- $\delta$ , $\gamma$ Inhibitor, in Combination with Romidepsin or Bortezomib in Relapsed/Refractory T-Cell Lymphoma. <i>Blood</i> , 2017, 130, 819-819.	1.4	12
139	Bone marrow fibrosis in chronic myelomonocytic leukemia is associated with increased megakaryopoiesis, splenomegaly and with a shorter median time to disease progression. <i>Oncotarget</i> , 2017, 8, 103274-103282.	1.8	12
140	Acute myeloid leukemia masquerading as hepatocellular carcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, E31-E35.	1.4	6
141	Seroma-associated anaplastic large-cell lymphoma arising on the background of subcutaneous calcinosis: beyond breast implants. <i>Histopathology</i> , 2016, 69, 890-892.	2.9	2
142	Single-Tube 10-Fluorochrome Analysis for Efficient Flow Cytometric Evaluation of Minimal Residual Disease in Plasma Cell Myeloma. <i>American Journal of Clinical Pathology</i> , 2016, 146, 41-49.	0.7	37
143	The Expanding Spectrum of Follicular Lymphoma. <i>Surgical Pathology Clinics</i> , 2016, 9, 29-40.	1.7	3
144	Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting. <i>Blood</i> , 2016, 127, 3004-3014.	1.4	244

#	ARTICLE	IF	CITATIONS
145	Crystal-storing histiocytosis: a clinicopathological study of 13 cases. <i>Histopathology</i> , 2016, 68, 482-491.	2.9	60
146	Correlation of histomorphological pattern of cardiac amyloid deposition with amyloid type: a histological and proteomic analysis of 108 cases. <i>Histopathology</i> , 2016, 68, 648-656.	2.9	48
147	D25V apolipoprotein C-III variant causes dominant hereditary systemic amyloidosis and confers cardiovascular protective lipoprotein profile. <i>Nature Communications</i> , 2016, 7, 10353.	12.8	50
148	Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. <i>Cancer Discovery</i> , 2016, 6, 154-165.	9.4	372
149	Genetically predicted longer telomere length is associated with increased risk of B-cell lymphoma subtypes. <i>Human Molecular Genetics</i> , 2016, 25, 1663-1676.	2.9	52
150	Clinical utility of morphology, immunohistochemistry, flow cytometry, and FISH analysis in monitoring of plasma cell neoplasms in the bone marrow. <i>Journal of Hematopathology</i> , 2016, 9, 9-18.	0.4	6
151	The many faces of small B cell lymphomas with plasmacytic differentiation and the contribution of MYD88 testing. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 468, 259-275.	2.8	97
152	A Phase Ib/IIa Trial of the Combination of Romidepsin, Lenalidomide and Carfilzomib in Patients with Relapsed/Refractory Lymphoma Shows Complete Responses in Relapsed and Refractory T-Cell Lymphomas. <i>Blood</i> , 2016, 128, 2991-2991.	1.4	21
153	Frequent Clinical Overlap of Histiocytic Neoplasms and WHO-Classified Myeloid Malignancies Leads to Functional Insights into the Cell-of-Origin of Histiocytoses. <i>Blood</i> , 2016, 128, 951-951.	1.4	3
154	Association of MHC-II, PD-L1, and FoxP3 with Disease Status and Outcomes in Patients with Hodgkin Lymphoma. <i>Blood</i> , 2016, 128, 1774-1774.	1.4	0
155	The oncogenic transcription factor IRF4 is regulated by a novel CD30/NF- $\kappa$ B positive feedback loop in peripheral T-cell lymphoma. <i>Blood</i> , 2015, 125, 3118-3127.	1.4	68
156	A genome-wide association study of marginal zone lymphoma shows association to the HLA region. <i>Nature Communications</i> , 2015, 6, 5751.	12.8	58
157	Leukocyte Cell-Derived Chemotaxin 2-Associated Amyloidosis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 2084-2093.	4.5	61
158	A comparison of immunohistochemistry and mass spectrometry for determining the amyloid fibril protein from formalin-fixed biopsy tissue. <i>Journal of Clinical Pathology</i> , 2015, 68, 314-317.	2.0	95
159	Immune independent crosstalk between lymphoma and myeloid suppressor CD14 <sup>+</sup> HLA-DR <sup>low/neg</sup> monocytes mediates chemotherapy resistance. <i>Onc Immunology</i> , 2015, 4, e996470.	4.6	10
160	Wild Edible Plants of Pertek (Tunceli-Turkey). <i>Marmara Pharmaceutical Journal</i> , 2015, 2, 126-126.	0.5	21
161	Cerebellar EBV-associated diffuse large B cell lymphoma following angioimmunoblastic T cell lymphoma. <i>Journal of Hematopathology</i> , 2015, 8, 235-241.	0.4	11
162	Proteomic Detection of Immunoglobulin Light Chain Variable Region Peptides from Amyloidosis Patient Biopsies. <i>Journal of Proteome Research</i> , 2015, 14, 1957-1967.	3.7	50

#	ARTICLE	IF	CITATIONS
163	Globular Hepatic Amyloid Is Highly Sensitive and Specific for LECT2 Amyloidosis. <i>American Journal of Surgical Pathology</i> , 2015, 39, 558-564.	3.7	33
164	Presence of PD-1 Expressing T Cells Predicts for Inferior Overall Survival in Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2015, 126, 1785-1785.	1.4	4
165	Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma. <i>Oncotarget</i> , 2015, 6, 9488-9501.	1.8	42
166	Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. <i>Blood</i> , 2015, 126, 481-481.	1.4	0
167	High-Depth, Targeted, Next Generation Sequencing Identifies Novel Genetic Alterations in Cutaneous T-Cell Lymphoma. <i>Blood</i> , 2015, 126, 1485-1485.	1.4	1
168	Defining the Incidence and Clinical Impact of Genomic Alterations Across Different Histologic Types of Lymphoma Using a Clinically Validated Comprehensive Targeted Sequencing Assay. <i>Blood</i> , 2015, 126, 2668-2668.	1.4	0
169	Distinctive Genomic Alterations in Testicular Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2015, 126, 3655-3655.	1.4	1
170	Clinical diagnosis and typing of systemic amyloidosis in subcutaneous fat aspirates by mass spectrometry-based proteomics. <i>Haematologica</i> , 2014, 99, 1239-1247.	3.5	140
171	Advances in clinical applications of tissue proteomics: opportunities and challenges. <i>Expert Review of Proteomics</i> , 2014, 11, 531-533.	3.0	9
172	Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDAâ€œNCI roundtable symposium. <i>American Journal of Hematology</i> , 2014, 89, 1159-1160.	4.1	52
173	Characterization and outcomes of renal leukocyte chemotactic factor 2-associated amyloidosis. <i>Kidney International</i> , 2014, 86, 370-377.	5.2	82
174	Medical History, Lifestyle, Family History, and Occupational Risk Factors for Lymphoplasmacytic Lymphoma/Waldenstrom's Macroglobulinemia: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , 2014, 2014, 87-97.	2.1	32
175	Pharmaceutical amyloidosis associated with subcutaneous insulin and enfuvirtide administration. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2014, 21, 71-75.	3.0	74
176	Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. <i>Nature Genetics</i> , 2014, 46, 1233-1238.	21.4	147
177	Genome-wide Association Study Identifies Five Susceptibility Loci for Follicular Lymphoma outside the HLA Region. <i>American Journal of Human Genetics</i> , 2014, 95, 462-471.	6.2	96
178	Clinical Proteome Informatics Workbench Detects Pathogenic Mutations in Hereditary Amyloidoses. <i>Journal of Proteome Research</i> , 2014, 13, 2352-2358.	3.7	40
179	Left Ventricular Amyloid Deposition in Patients With Heart Failure and Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2014, 2, 113-122.	4.1	309
180	Leukocyte cell-derived chemotaxin 2 (LECT2)â€œassociated amyloidosis is a frequent cause of hepatic amyloidosis in the United States. <i>Blood</i> , 2014, 123, 1479-1482.	1.4	70

#	ARTICLE	IF	CITATIONS
181	ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. <i>Blood</i> , 2014, 124, 1473-1480.	1.4	401
182	Clarifying immunoglobulin gene usage in immunoglobulin light chain amyloidosis by mass spectrometry of amyloid in clinical tissue specimens. <i>Journal of Clinical Oncology</i> , 2014, 32, 8605-8605.	1.6	1
183	Amyloidosis of the breast: predominantly AL type and over half have concurrent breast hematologic disorders. <i>Modern Pathology</i> , 2013, 26, 232-238.	5.5	56
184	Shotgun proteomics-based clinical testing for diagnosis and classification of amyloidosis. <i>Journal of Mass Spectrometry</i> , 2013, 48, 1067-1077.	1.6	62
185	Relationship between monoclonal gammopathy and cardiac amyloid type. <i>Cardiovascular Pathology</i> , 2013, 22, 189-194.	1.6	52
186	Renal Amyloidosis Associated With a Novel Sequence Variant of Gelsolin. <i>American Journal of Kidney Diseases</i> , 2013, 61, 161-166.	1.9	47
187	Exploring the amyloid proteome in immunoglobulin-derived lymph node amyloidosis using laser microdissection/tandem mass spectrometry. <i>American Journal of Hematology</i> , 2013, 88, 577-580.	4.1	18
188	Nodular Pulmonary Amyloidosis Is Characterized by Localized Immunoglobulin Deposition and Is Frequently Associated With an Indolent B-cell Lymphoproliferative Disorder. <i>American Journal of Surgical Pathology</i> , 2013, 37, 406-412.	3.7	105
189	Profiling Genomic Alterations Of Diffuse Large B-Cell Lymphoma (DLBCL) At Diagnosis, Relapse, and Transformation, Using a Novel Clinical Diagnostic Targeted Sequencing Platform. <i>Blood</i> , 2013, 122, 1761-1761.	1.4	3
190	Proteome Of Amyloidosis: Mayo Clinic Experience In 4139 Cases. <i>Blood</i> , 2013, 122, 1900-1900.	1.4	13
191	Whole-Exome Analysis Of DLBCL Tumors Reveals a Unique Genetic Signature Associated With Aggressive Disease. <i>Blood</i> , 2013, 122, 499-499.	1.4	2
192	A Genome-Wide Association Study (GWAS) Of Event-Free Survival In Diffuse Large B-Cell Lymphoma (DLBCL) Treated With Rituximab and Anthracycline-Based Chemotherapy: A Lysa and Iowa/Mayo Clinic SPORE Multistage Study. <i>Blood</i> , 2013, 122, 76-76.	1.4	1
193	Deep Proteomic Profiling Predicts Differential Chemosensitivity In Anaplastic Large Cell Lymphoma Cell Lines. <i>Blood</i> , 2013, 122, 1670-1670.	1.4	0
194	Activation Of TAK1 By MYD88 L265P Drives Malignant B Cell Growth In Non-Hodgkin Lymphomas. <i>Blood</i> , 2013, 122, 245-245.	1.4	1
195	Mass Spectrometry-Based Proteomics Reveals Distinct Immunoglobulin Light Chain Variable Region Usage In Systemic Versus Localized AL Amyloidosis. <i>Blood</i> , 2013, 122, 3142-3142.	1.4	0
196	Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 3879-3884.	7.1	853
197	Hereditary Systemic Amyloidosis Due to Asp76Asn Variant $\beta_2$ -Microglobulin. <i>New England Journal of Medicine</i> , 2012, 366, 2276-2283.	27.0	172
198	Laser microdissection and mass spectrometry-based proteomics aids the diagnosis and typing of renal amyloidosis. <i>Kidney International</i> , 2012, 82, 226-234.	5.2	166

#	ARTICLE	IF	CITATIONS
199	Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas. <i>Blood</i> , 2012, 120, 2280-2289.	1.4	208
200	Localized insulinâ€derived amyloidosis: A potential pitfall in the diagnosis of systemic amyloidosis by fat aspirate. <i>American Journal of Hematology</i> , 2012, 87, E131-2.	4.1	34
201	A Phase II Trial of R-CHOP Followed by Zevalin Radioimmunotherapy for Patients with Previously Untreated Stages I and II CD20+ Diffuse Large Cell Non-Hodgkin's Lymphoma: an Eastern Cooperative Oncology Group Study (E3402).. <i>Blood</i> , 2012, 120, 2687-2687.	1.4	2
202	MYD88 Pathway Activation in Lymphoplasmacytic Lymphoma Drives Tumor Cell Growth and Cytokine Expression.. <i>Blood</i> , 2012, 120, 2699-2699.	1.4	3
203	Renal Heavy Chain and Heavy+Light Chain Amyloidosis: A Report of 17 Cases and Comparison with Renal Light Chain Amyloidosis. <i>Blood</i> , 2012, 120, 3992-3992.	1.4	1
204	EBV(+) Diffuse Large B Cell Lymphoma Is Infrequent in Upper Central United States and Lacks Unique Clinical Characteristics or Adverse Prognosis Compared to EBV (âˆ) Counterparts: Results From University of Iowa/Mayo Clinic SPORE. <i>Blood</i> , 2012, 120, 1604-1604.	1.4	1
205	The Presence of Intratumoral CD14 Positive Cells Is Associated with Transformation of Follicular Lymphoma to Diffuse Large B Cell Lymphoma.. <i>Blood</i> , 2012, 120, 2700-2700.	1.4	31
206	Expression of MYC but Not pSTAT3 Is an Adverse Prognostic Factor for Diffuse Large B Cell Lymphoma (DLBCL) Treated with Epratuzumab/R-CHOP. <i>Blood</i> , 2012, 120, 1575-1575.	1.4	0
207	A Structural Basis for p53-Deficiency, Deregulated Cell Cycle and Unfavorable Outcome in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2012, 120, 1534-1534.	1.4	0
208	Diagnostic Accuracy of a Defined Immunophenotypic and Molecular Genetic Approach for Peripheral T/NK-Cell Lymphomas: A North American PTCL Study Group Project. <i>Blood</i> , 2012, 120, 1545-1545.	1.4	6
209	Germline Genetic Variation and Risk of Follicular Lymphoma Transformation in the Modern Treatment Era. <i>Blood</i> , 2012, 120, 149-149.	1.4	0
210	Non-Follicular Low Grade B-Cell Lymphomas: Patterns of Presentation and Management with Comparative Prognostic Utility of IPI and FLIPI. <i>Blood</i> , 2012, 120, 1563-1563.	1.4	0
211	Expression but Not Promoter Hypermethylation of the Tyrosine Phosphatase PTPN6 Is Associated with Activated STAT3 and Inferior Prognosis in Diffuse Large B Cell Lymphoma Molecular Subtypes.. <i>Blood</i> , 2012, 120, 2655-2655.	1.4	0
212	Prognostic Value of Six Germline Single Nucleotide Polymorphisms At the REL, HLA-DRA, GATA3 and PVT1 Loci Identified in a Classical Hodgkin Lymphoma Genome-Wide Association Study: A Meta-Analysis of 601 Patients for Progression-Free Survival From Two Independent Studies. <i>Blood</i> , 2012, 120, 3637-3637.	1.4	0
213	CXCR5 Polymorphisms in Non-Hodgkin Lymphoma (NHL) Risk and Prognosis.. <i>Blood</i> , 2012, 120, 2702-2702.	1.4	0
214	Amyloidogenicity and Clinical Phenotype Associated with Five Novel Mutations in Apolipoprotein A-I. <i>American Journal of Pathology</i> , 2011, 179, 1978-1987.	3.8	111
215	Strong Transthyretin Immunostaining. <i>American Journal of Surgical Pathology</i> , 2011, 35, 1685-1690.	3.7	62
216	Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing. <i>Blood</i> , 2011, 117, 915-919.	1.4	279

#	ARTICLE	IF	CITATIONS
217	Mass Spectrometry-Based Proteomic Analysis of Amyloid Neuropathy Type in Nerve Tissue. Archives of Neurology, 2011, 68, 195-9.	4.5	101
218	ALK-Negative Anaplastic Large Cell Lymphomas with 6p25.3 Translocations Show a Histone-Modifying Gene Expression Signature. Blood, 2011, 118, 88-88.	1.4	3
219	Dysregulation of GPR34 in Indolent Lymphomas and Its Function As a Novel Regulator of Cell Growth and Gene Expression. Blood, 2011, 118, 1570-1570.	1.4	15
220	Elevated Serum IL-10 Levels in Patients with Diffuse Large B Cell Lymphoma: A Mechanism of Aberrant JAK2 Kinase Activation. Blood, 2011, 118, 960-960.	1.4	0
221	Distinctive Patterns of Intraclonal Diversification In IGHV1-2*04 Immunoglobulin Receptors of Patients with Splenic Marginal Zone Lymphoma: A of Ongoing Interactions with Antigen?. Blood, 2011, 118, 2638-2638.	1.4	0
222	Silencing of SHP1 Is Frequent in Phospho-STAT3 Positive Diffuse Large Cell Lymphoma and This Silencing Is Independent of Methylation of CpG Islands,. Blood, 2011, 118, 3678-3678.	1.4	0
223	The Mutational Landscape of Diffuse Large B Cell Lymphoma. Blood, 2011, 118, 259-259.	1.4	0
224	Mass Spectrometry-Based Proteomic Diagnosis of Renal Immunoglobulin Heavy Chain Amyloidosis. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 2180-2187.	4.5	109
225	Diagnosis of Nodal Peripheral T-Cell Lymphomas. Surgical Pathology Clinics, 2010, 3, 955-988.	1.7	1
226	Pitfalls in the Diagnosis of Primary Amyloidosis. Clinical Lymphoma, Myeloma and Leukemia, 2010, 10, 177-180.	0.4	46
227	A Newly Identified Translocation t(X;14)(p11;q32) In MALT Lymphoma Involving IGHS and GPR34 Reveals A Novel Role for GPR34 In Cell Growth and Tumor Development. Blood, 2010, 116, 1999-1999.	1.4	0
228	Massively Parallel Mate Pair DNA Library Sequencing for Translocation Discovery: Recurrent t(6;7)(p25.3;q32.3) Translocations In ALK-Negative Anaplastic Large Cell Lymphomas. Blood, 2010, 116, 633-633.	1.4	1
229	Expression of Interferon Regulatory Factor-4 (IRF4/MUM1) Is Associated with Inferior Overall Survival In Peripheral T-Cell Lymphoma. Blood, 2010, 116, 140-140.	1.4	10
230	Proteomic Analysis of Immunoglobulin Light Chains (LC) In AL Amyloidosis Shows That the Sequence of Clonal LC Secreted by the Neoplastic Plasma Cells Is Identical to the LC Deposited In the Amyloid Plaques. Blood, 2010, 116, 1909-1909.	1.4	0
231	Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood, 2009, 114, 4957-4959.	1.4	746
232	A Case of Insulin Resistance Secondary to Insulin Induced Localized Cutaneous Amyloidosis.. Blood, 2009, 114, 4908-4908.	1.4	7
233	Germline Variation in Apoptosis Pathway Genes and Risk of Non-Hodgkin Lymphoma.. Blood, 2009, 114, 3933-3933.	1.4	1
234	MYC Translocations Are Associated with Poor Overall Survival in DLBCL Patients in Both the Chemotherapy and Immunochemotherapy Eras.. Blood, 2009, 114, 443-443.	1.4	0

#	ARTICLE	IF	CITATIONS
235	Elevated Expression of GPR34 in Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma and Its Association with Increased Cell Growth, Erk Activation, and AP-1 and CRE-Mediated Transcription.. Blood, 2009, 114, 3927-3927.	1.4	1
236	Immunoglobulin derived depositions in the nervous system: novel mass spectrometry application for protein characterization in formalin-fixed tissues. Laboratory Investigation, 2008, 88, 1024-1037.	3.7	103
237	Diagnosis and Classification of Amyloidosis in Abdominal Subcutaneous Fat Aspiration Specimens Using Mass Spectrometry Based Proteomics. Blood, 2008, 112, 2710-2710.	1.4	2
238	Gene Expression Profiling of Post-Follicular B-Cell Lymphoma. Blood, 2008, 112, 617-617.	1.4	0
239	A Clinical Test for the Identification of Amyloid Proteins in Biopsy Specimens by a Novel Method Based on Laser Microdissection and Mass Spectrometry.. Blood, 2007, 110, 1480-1480.	1.4	3
240	Syk Tyrosine Kinase Is Overexpressed in the Majority of Peripheral T- and NK-Cell Lymphomas, and Represents a Potential Therapeutic Target.. Blood, 2007, 110, 690-690.	1.4	3
241	Mucosa-associated lymphoid tissue (MALT) lymphoma: a practical guide for pathologists. Journal of Clinical Pathology, 2006, 60, 361-372.	2.0	144
242	Angioimmunoblastic T-cell lymphoma: a neoplasm of germinal-center T-helper cells?. Blood, 2005, 106, 1501-1502.	1.4	161
243	Intravascular Lymphoma: Poor Outcomes May Be Improved with Aggressive Therapy.. Blood, 2005, 106, 938-938.	1.4	8
244	Angioimmunoblastic T-Cell Lymphoma: A Large Series Outcome Analysis.. Blood, 2005, 106, 2810-2810.	1.4	1